Radical gastrectomy with D2 lymph node dissection after neoadjuvant therapy

作者
Marian BAKOS,T. Jankovič,Stefan DURDIK,Ľ Danihel
出处
期刊:Bratislavské lekárske listy [AEPress]
卷期号:123 (11): 777-784 被引量:1
标识
DOI:10.4149/bll_2022_125
摘要

OBJECTIVES: This study focuses on the evaluation of the effectiveness of radical gastrectomy with D2 node dissection after neoadjuvant therapy in the patients with gastric cancer. Gastric cancer is a widespread type of cancer, and it is the third leading cause of death in the cancer patients. Metastases most often occur in the lymph nodes and therefore, in addition to gastrectomy, lymph node dissection is often performed in the patients. We are distinguishing between D1, 2 and 3 dissections. As with other cancers, the effectiveness of neoadjuvant therapy is being considered, which aims to improve the patient's prognosis and thus the 5-year survival rate. METHODS: Within the study, we evaluated a group of the patients diagnosed with gastric cancer (n = 41). The average age of the patients was 62.3 years (20-72 years). 68.3 % (n = 28) patients underwent neoadjuvant therapy before surgery, the remaining 31.7 % (n = 13) underwent only radical gastrectomy with D2 lymphadenectomy. In all the cases, an open operational approach was implemented. CONCLUSION: Lymphadenopathy was found in 85.4 % of the patients. Complications occurred in both groups, but in the group with neoadjuvant therapy their share was lower (14.3 % vs 23.1 %), while in the group without neoadjuvant treatment the proportion of duodenal leaks was higher, as well as the number of reoperations. In total, an average of 30 ± 8 lymph nodes were harvested. A lower number of T3-4 cases was found in the neoadjuvant group (17.9 % vs 61.6 %), confirming that the tumour size was significantly smaller in the neoadjuvant group than in the group, who did not undergo it and underwent only surgical treatment. Relapse was found in 29.3 % of the patients after neoadjuvant treatment and in 38.5 % of the patients without neoadjuvant treatment. Also, mortality due to relapse was higher in the group without neoadjuvant treatment (30.8 % vs 21.7 %). The average survival was 25 months (Tab. 3, Fig. 3, Ref. 60).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
zzx发布了新的文献求助10
2秒前
田好好发布了新的文献求助10
3秒前
星辰大海的应助被科研通管家采纳,获得10
3秒前
坚强冰枫的应助被科研通管家采纳,获得10
3秒前
Firsterchao的应助被科研通管家采纳,获得30
3秒前
huang的应助被科研通管家采纳,获得10
3秒前
OK的应助被科研通管家采纳,获得150
3秒前
上官若男的应助被科研通管家采纳,获得10
3秒前
4秒前
Firsterchao的应助被科研通管家采纳,获得30
4秒前
4秒前
所所的应助被科研通管家采纳,获得10
4秒前
奥利奥发布了新的文献求助10
4秒前
4秒前
wanci的应助被科研通管家采纳,获得30
4秒前
4秒前
4秒前
null的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
坚强冰枫的应助被科研通管家采纳,获得10
4秒前
Elias发布了新的文献求助10
4秒前
4秒前
尊敬店员的应助被科研通管家采纳,获得20
4秒前
5秒前
乐乐的应助被科研通管家采纳,获得10
5秒前
5秒前
Akim的应助被科研通管家采纳,获得10
5秒前
Akim的应助被哭热采纳,获得10
5秒前
6秒前
7秒前
8秒前
9秒前
CiCi完成签到 ,获得积分10
9秒前
小蘑菇的应助被羲和采纳,获得10
10秒前
11秒前
11秒前
jd完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition 800
Comprehensive Heterocyclic Chemistry IV 400
Qualitative Methodologies in Tourism Studies: Disrupting and Co-creating Critical Research 350
Représentation chimique de la structure des kérogènes et des asphaltènes en fonction de leur origine et de leur degré d'évolution 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8051691
求助须知:如何正确求助?哪些是违规求助? 9479625
关于积分的说明 21298839
捐赠科研通 7620027
什么是DOI,文献DOI怎么找? 3393536
关于科研通互助平台的介绍 2524818
邀请新用户注册赠送积分活动 2431558